Seroprevalence of SARS-CoV-2 antibodies during the third wave of COVID-19 in the Seoul metropolitan area of Korea
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
OBJECTIVES: After the third wave of coronavirus disease 2019 (COVID-19) , by mid-February 2021, approximately 0.16% of the Korean population was confirmed positive, which appeared to be among the lowest rates worldwide at that time. However, asymptomatic transmission is challenging for COVID-19 surveillance. Therefore, a community-based serosurvey of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted to understand the effectiveness of Korea’s strong containment strategy. METHODS: We collected 5,002 residual sera samples from January 30 to March 3, 2021, from 265 medical facilities in Seoul, 346 in Gyeonggi Province, and 57 in Incheon. Sixty samples from tertiary institutions were excluded. We defined the sub-regions according to the addresses of the medical facilities where the specimens were collected. Elecsys Anti-SARS-CoV-2 was used for screening, and positivity was confirmed using the SARS-CoV-2 sVNT Kit. Prevalence was estimated using sampling weights and the Wilson score interval for a binomial proportion with a 95% confidence interval. RESULTS: Among the 4,942 specimens, 32 and 25 tested positive for COVID-19 in the screening and confirmatory tests, respectively. The overall crude prevalence of SARS-CoV-2 antibodies was 0.51%. The population-adjusted overall prevalence was 0.55% in women and 0.38% in men. The region-specific estimation was 0.67% and 0.30% in Gyeonggi Province and Seoul, respectively. No positive cases were detected in Incheon. CONCLUSIONS: The proportion of undetected cases in Korea remained low as of early 2021 . Therefore, an infection control strategy with exhaustive tracing and widespread pre-emptive testing appears to be effective in containing community spread of COVID-19.
Abstract
OBJECTIVES: After the third wave of coronavirus disease 2019 (COVID-19) , by mid-February 2021, approximately 0.16% of the Korean population was confirmed positive, which appeared to be among the lowest rates worldwide at that time. However, asymptomatic transmission is challenging for COVID-19 surveillance. Therefore, a community-based serosurvey of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted to understand the effectiveness of Korea’s strong containment strategy. METHODS: We collected 5,002 residual sera samples from January 30 to March 3, 2021, from 265 medical facilities in Seoul, 346 in Gyeonggi Province, and 57 in Incheon. Sixty samples from tertiary institutions were excluded. We defined the sub-regions according to the addresses of the medical facilities where the specimens were collected. Elecsys Anti-SARS-CoV-2 was used for screening, and positivity was confirmed using the SARS-CoV-2 sVNT Kit. Prevalence was estimated using sampling weights and the Wilson score interval for a binomial proportion with a 95% confidence interval. RESULTS: Among the 4,942 specimens, 32 and 25 tested positive for COVID-19 in the screening and confirmatory tests, respectively. The overall crude prevalence of SARS-CoV-2 antibodies was 0.51%. The population-adjusted overall prevalence was 0.55% in women and 0.38% in men. The region-specific estimation was 0.67% and 0.30% in Gyeonggi Province and Seoul, respectively. No positive cases were detected in Incheon. CONCLUSIONS: The proportion of undetected cases in Korea remained low as of early 2021 . Therefore, an infection control strategy with exhaustive tracing and widespread pre-emptive testing appears to be effective in containing community spread of COVID-19.
참고문헌 (26)
- "COVID-19 data repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University"[URL]
- "SARS-CoV-2 variants"[URL]
- Mohiuddin M, "Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options", Respir Med, 191, pp.106716~ (2022)
- Kang J, "South Korea’s responses to stop the COVID-19 pandemic", Am J Infect Control, 48, pp.1080~1086 (2020)
- "COVID-19 outbreak and vaccination status in Korea"[URL]
- Al-Qahtani M, "The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjec9.ts", Int J Infect Dis, 102, pp.285~288 (2021)
- Kronbichler A, "Asymptomatic patients as a source of COVID-19 infections : a systematic review and meta-analysis", Int J Infect Dis, 98, pp.180~186 (2020)
- Rothe C, "Transmission of 2019-nCoV infection from an asymptomatic contact in Germany", N Engl J Med, 382, pp.970~971 (2020)
- Bobrovitz N, "Global seroprevalence of SARS-CoV-2 antibodies : a systematic review and meta-analysis", PLoS One, 16, pp.e0252617~ (2021)
- Kim Ah-Ra, "Seroprevalence of SARS-CoV-2 antibodies in the community based on participants in the 2020 Korea National Health and Nutrition Examination Survey", Epidemiology and Health, 44, pp.1~6 (2022), 한국역학회[DOI]
- Kwon SY, "Post-donation COVID-19 identification in blood donors", Vox Sang, 115, pp.601~602 (2020)
- Nah EH, "Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea : a cross-sectional study", BMJ Open, 11, pp.e049837~ (2021)
- 노지윤, "Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea", Journal of Korean Medical Science, 35(33), pp.1~6 (2020), 대한의학회[DOI]
- Daniel WW, "Biostatistics: a foundation for analysis in the health sciences" (2018), Wiley
- Naing L, "Practical issues in calculating the sample size for prevalence studies", Arch Orofac Sci, 1, pp.9~14 (2006)
- Muench P, "Development and validation of the elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2", J Clin Microbiol, 58, pp.e01694~e01720 (2020)
- Valcourt EJ, "Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)", Diagn Microbiol Infect Dis, 99, pp.115294~ (2021)
- Brown LD, "Interval estimation for a binomial proportion", Stat Sci, 16, pp.101~117 (2001)
- Song Suk-Kyoon, "IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea", Journal of Korean Medical Science, 35(29), pp.1~8 (2020), 대한의학회[DOI]
- Kim Yu Kyung, "Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea", Journal of Korean Medical Science, 36(43), pp.1~9 (2021), 대한의학회[DOI]
- Byambasuren O, "Estimating the extent of asymptomatic COVID-19 and its potential for community transmission : systematic review and meta-analysis", J Assoc Med Microbiol Infect Dis Can, 5, pp.223~234 (2020)
- Oliu-Barton M, "SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties", Lancet, 397, pp.2234~2236 (2021)
- Coatsworth N, "Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia : a prospective surveillance study", ANZ J Surg, 91, pp.27~32 (2021)
- Gidding HF, "Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020", Med J Aust, 214, pp.179~185 (2021)
- "COVID-19 weekly surveillance reports - archive"[URL]
- Bobrovitz N, "Global seroprevalence of SARS-CoV-2 antibodies : a systematic review and meta-analysis", PLoS One, 16, pp.e0252617~ (2021)